Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu SIGLEC8 PE

Anti-Hu SIGLEC8 PE

Regulatory status

RUO

Antigen

SIGLEC8

Clone

7C9

Format

Reactivity

Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

1P-846-T100

Ask for delivery term HERE

242.00 USD

Variant

100 tests

1P-846-T100

Ask for delivery term HERE

242.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The mouse monoclonal antibody 7C9 recognizes an extracellular epitope of SIGLEC8, an eosinophil marker, expressed e.g. in lymph nodes and spleen.

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Reactivity

Human

Immunogen

Extracellular domain of human SIGLEC8 fused with Fc fragment of human IgG1

Preparation

Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

SAF2

Antigen description

SIGLEC8 is a sialic acid binding lectin similar to CD33. In its cytoplasmic comain it contains an immunoreceptor tyrosine-based inhibitory motif (ITIM), and a motive similar to a binding site for SLAM-associated protein. SIGLEC8 is expressed e.g. in lymph nodes and spleen. It is an eosinophil marker, although it can be found also on the surface of mast cells. Crosslinking of SIGLEC8 leads to apoptosis. Soluble form of SIGLEC8 can be foud in human serum, especially in case of eosinophil-associated diseases.

Entrez Gene ID 27181

UniProt ID Q9NYZ4

Separation of human SIGLEC8 positive eosinophil granulocytes (red-filled) from eosinophil granulocytes (black-dashed) stained using mouse IgG1 isotype control (MOPC-21) PE antibody (concentration in sample 1,7 μg/ml, same as SIGLEC8 PE concentration, black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human SIGLEC8 (7C9) APC antibody (10 μl reagent / 100 μl of peripheral whole blood).

Product specific references:

Galeotti C, Stephen-Victor E, Karnam A, Das M, Gilardin L, Maddur MS, Wymann S, Vonarburg C, Chevailler A, Dimitrov JD, Benveniste O, Bruhns P, Kaveri SV, Bayry J: Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. J Allergy Clin Immunol. 2019 Aug;144(2):524-535.e8.
PubMed

Kano G, Bochner BS, Zimmermann N: Regulation of Siglec-8-induced intracellular reactive oxygen species production and eosinophil cell death by Src family kinases. Immunobiology. 2017 Feb;222(2):343-349.
PubMed

Arakawa S, Suzukawa M, Ohshima N, Tashimo H, Asari I, Matsui H, Kobayashi N, Shoji S, Nagase T, Ohta K: Expression of Siglec-8 is regulated by interleukin-5, and serum levels of soluble Siglec-8 may predict responsiveness of severe eosinophilic asthma to mepolizumab. Allergol Int. 2018 Sep;67S:S41-S44.
PubMed

Kano G, Almanan M, Bochner BS, Zimmermann N: Mechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activation. J Allergy Clin Immunol. 2013 Aug;132(2):437-45.
PubMed